Compare · AIKI vs ASH
AIKI vs ASH
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Ashland Inc. (ASH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and ASH operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- ASH is the larger of the two at $3.28B, about 76.3x AIKI ($42.9M).
- ASH has hit the wire 2 times in the past 4 weeks while AIKI has been quiet.
- ASH has more recent analyst coverage (25 ratings vs 1 for AIKI).
- Company
- AIkido Pharma Inc.
- Ashland Inc.
- Price
- -
- -
- Market cap
- $42.9M
- $3.28B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 25
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Ashland Inc.
Ashland Global Holdings Inc. provides specialty chemical solutions worldwide. The company's Specialty Ingredients segment offers products, technologies, and resources for solving formulation and product-performance challenges. It provides solutions using natural, synthetic, and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extracts. This segment offers its solutions for the pharmaceutical companies; makers of personal care products, food, and beverages; makers of nutraceuticals and supplements; manufacturers of paint, coatings, and construction materials; packaging and converting markets; and oilfield service companies. Its Intermediates and Solvents produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone that are used as chemical intermediates in the production of engineering polymers and polyurethanes, as well as specialty process solvents used in electronics, pharmaceuticals, water filtration membranes, and others. The company was formerly known as Ashland Inc. and changed its name to Ashland Global Holdings Inc. in September 2016. Ashland Global Holdings Inc. was founded in 1924 and is based in Wilmington, Delaware.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest ASH
- SEC Form 4 filed by Director Bishop Steven D
- SEC Form 4 filed by Director Chattopadhyay Sanat
- SEC Form 8-K filed by Ashland Inc.
- SVP and CTO Musa Osama M exercised 10,418 shares at a strike of $69.06 and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 22% to 37,577 units (SEC Form 4)
- Ashland scales Transformed Vegetable Oils technology platform in crop care, launches agrimer™ eco-disperse OD polymeric dispersant
- SEC Form 4 filed by SVP and CTO Musa Osama M
- Ashland Innovation Day to be held September 17, 2026
- Ashland to host Innovation Day for analysts and investors
- Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
- Amendment: SEC Form SCHEDULE 13G/A filed by Ashland Inc.